Kiniksa touts 3rd approval for aging Arcalyst — a good haul for just $5M in cash it paid Regeneron for the drug
Kiniksa bet $5 million cash back in 2017 that Regeneron’s Arcalyst could help patients with recurrent pericarditis, a painful autoinflammatory heart disease. Now, more than …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
